Several studies show a link between ERCC1 and RRM1 alone or in combination with other biomarkers to drug sensitivity, progression-free survival or overall survival in lung cancer [11, 12] and in MM [13–15] We have also seen indication that ERCC1 and RRM1 immunoreactivity may explain the sensitivity of MM cell lines to carboplatin [16]. The gene discussed is ERCC1; the disease is Miyoshi myopathy.